Immutep Ltd has released a press release.
Completion of Share Purchase Plan
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- US FDA & IRB approves start of ph2b head & neck cancer trial
- Efti to be evaluated in new triple combination therapy trial
- Immutep secures commitments for A$60 million in a Placement
- Immutep global webcast slides
- Immutep Reveals a New anti-LAG-3 Research Program
Later from Immutep
- Completion of Placement - Tranche 2
- INSIGHT-003 investigator-initiated trial - 1st patient dosed
- Chinese patent granted for anti-LAG-3 antibody LAG525
- Immuteps partner, EOC Pharma, expands efti trial pipeline
- Recruitment of patients completed for Part B of TACTI-002
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep